Publications

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

JAMA Oncology 4(8), 1080–1084

Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, … Park W, …

The Oncologist 24(6), 820–828

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, … Park W, …

Cancer Immunology, Immunotherapy 69(7), 1177–1187

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al.

N Engl J Med